The U.S. neurological devices market looks set for appreciable growth, especially due to the major unmet clinical need for the treatment of neurological disorders. Moreover, the neurological devices market addresses large patient pools. The United States estimated around 140.0 million people afflicted with neurological disorders (chronic pain, migraine, essential tremor, stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease, and dystonia), thus highlighting the underlying growth.
New analysis from Frost & Sullivan (http://www.frost.com/prod/servlet/finsvc-home.pag), U.S. Neurological Devices Market - Investment Analysis, finds that the market is expected to exhibit a strong growth of 17.6 percent for the period 2006-2011.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the U.S. Neurological Devices Market - Investment Analysis, then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via e-mail upon receipt of the above information.
“Unmet clinical need for the treatment of neurological disorders and a large unaddressed patient pool are expected to spur the growth of the U.S. neurological devices market in the coming years,” notes Frost & Sullivan Financial Analyst Sheetal Rajani. “This apart, the aging U.S. population is also expected to drive the demand for neurological devices, as the risk of neurological disorders such as that of stroke, Alzheimer’s disease, Parkinson’s disease, and epilepsy increase with age.”
To illustrate this with an example, industry sources revealed during 2004-2005, prevalence of stroke was much higher for the population aged above 85 at 13.5 percent; opposed to the age group of 45-64 at 2.3 percent. Furthermore, people above the age of 65 account for approximately 72.0 percent who suffer from a stroke, further highlighting the importance of this cohort for neurological devices market.
Among the market segments, the neurostimulation segment — the fastest growing segment, holds tremendous investment potential for venture capital investors. The interventional neuroradiology segment comprised devices that aim at treating stroke-related circulatory problems. In this segment, exists significant growth potential for devices that treat ischemic stroke, which currently account for 83.0 percent of all strokes, and the devices used to treat them presently account for less than 15.0 percent of the total neurointerventional market.
“However, a lack of awareness about neurological conditions such as stroke has hindered the market from realizing its full potential,” says Rajani. “Although stroke is the third leading cause of death in the U.S., a lack of cognizance on part of the patient population has cost many lives that could have otherwise been saved. Accordingly, patient education is considered to be the need of the hour.”
Overall, neurology has the potential to achieve cardiology’s fortunes. Significant investment potential exists for venture capitalists in companies that research new clinical applications, such as neurostimulation devices and companies developing devices that treat ischemic strokes. Strategic buyers look to expand their neurostimulation portfolios, and with rewarding exit multiples witnessed in the past; this segment holds tremendous investment opportunity.
U.S. Neurological Devices Market - Investment Analysis is part of the Financial Services Medical Devices Subscription Growth Partnership Services. It provides an analysis of the key investment themes, segment profitability, merger and acquisition history, and various valuation indicators of neurological devices companies. In this research, Frost & Sullivan's expert analysts thoroughly examine the following segments: cerebro spinal fluid (CSF) management, interventional neuroradiology, neurosurgery, and neurostimulation. Interviews with the press are available.
Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan’s Growth Partnerships, visit http://www.frost.com